Detecting non-adherence by urine analysis in patients with uncontrolled hypertension: Rates, reasons and reactions

Journal of Human Hypertension

Volumn 31, Issue 4, 2017, Pages 253-257

  Pucci, M ^a   Martin, U ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADVERSE DRUG REACTION; ARTICLE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MEMORY DISORDER; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY; TREATMENT REFUSAL; URINALYSIS; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; URINE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES;

EID: 84987670128     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2016.69     Document Type: Article

References (22)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419.
2. Yiannakopoulou ECh, Papdopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12: 243-249.
3. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376 162 patients. Am J Med 2012; 125: 882-887.
4. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336(7653): 1114-1117.
5. Horne R, Weinman J, Barber N. Concordance, adherence and compliance in medicine taking. Report for the national co-ordinating centre for NHS service delivery and organisation research and development. 2005. Available from http:// www.nets.nihr.ac.uk/-data/assets/pdf-file/0009/64494/FR-08-1412-076.pdf. Accessed on January 2016.
6. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377-1378.
7. Chobanian AV. Impact of nonadherence to antihypertensive therapy. Circulation 2009; 120(16): 1558-1560.
8. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62: 218-225.
9. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J et al. High rates of non-adherence to antihypertensive treatment revealed by high-pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) urine analysis. Heart 2014; 100(11): 855-861.
10. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766-774.
11. Wright JM, Lee C, Chambers GK. Real-world effectiveness of antihypertensive drugs. CMAJ 2000; 162: 190-191.
12. Anderson JL, Dodman S, Kopelman M. Patient information recall in a rheumatology clinic. Rheumatol Rehabil 1979; 18(1): 18-22.
13. Osterberg L, Blaschke T. Adherence to medication. N Eng J Med 2005; 353: 487-497.
14. Myers MG. Compliance in hypertension: why don't patients take their pills? CMAJ 1999; 160: 64-65.
15. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23(8): 1296-1310.
16. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Databse Syst Rev 2004; (2) CD004804.
17. Leenen FH, Wilson TW, Bolli P, Larochelle P, Myers M, Handa SP et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997; 13(10): 914-920.
18. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD. The UMPIRE randomized clinical trial. JAMA 2013; 310(9): 918-929.
19. van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virusinfected men and women. AIDS Patient Care STDS 2002; 16: 269-281.
20. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of the literature. J Clin Psychiatry 2002; 63: 892-909.
21. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005; 61(1): 133-155.
22. Adams A, Uratsu C, Dyer W, Magid D, O'Connor P, Beck A et al. Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA 2013; 173(1): 54-61.